Skip to main content
SpringerLink
Log in

Novel Antischizophrenia Treatments

  • Book
  • © 2012

Overview

Editors:
  1. Mark A. Geyer

    1. Dept. Psychiatry, University of California San Diego, La Jolla, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Gerhard Gross

    1. Institut für Pharmakologie, Universität, Neuroscience Research, Abbott GmbH & Co. KG, Ludwigshafen, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Provide up-to-date information on approaches to the discovery of treatments for cognitive deficits in schizophrenia
  • Provide information on promising new targets for therapeutics in the treatment of schizophrenia
  • Describe potential use of adjunctive co-treatments for use together with traditional antipsychotics
  • Includes supplementary material: sn.pub/extras

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 213)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 349.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 449.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (14 chapters)

  1. Front Matter

    Pages i-x
    Download chapter PDF

  2. Clinical Instruments to Evaluate and Guide Treatment in Schizophrenia

    • Stephen R. Marder
    Pages 1-10

  3. Cognitive Impairment in Schizophrenia

    • Richard S. E. Keefe, Philip D. Harvey
    Pages 11-37

  4. Behavioral Animal Models to Assess Pro-cognitive Treatments for Schizophrenia

    • Jared W. Young, Nurith Amitai, Mark A. Geyer
    Pages 39-79

  5. Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia

    • Hsun-Hua Chou, Elizabeth Twamley, Neal R. Swerdlow
    Pages 81-111

  6. Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment

    • Colm M. P. O’Tuathaigh, Lieve Desbonnet, John L. Waddington
    Pages 113-145

  7. 5-HT2C Agonists as Therapeutics for the Treatment of Schizophrenia

    • Sharon Rosenzweig-Lipson, Thomas A. Comery, Karen L. Marquis, Jonathan Gross, John Dunlop
    Pages 147-165

  8. The Role of Dopamine D3 Receptors in Antipsychotic Activity and Cognitive Functions

    • Gerhard Gross, Karla Drescher
    Pages 167-210

  9. Nicotinic Mechanisms in the Treatment of Psychotic Disorders: A Focus on the α7 Nicotinic Receptor

    • Ann Olincy, Robert Freedman
    Pages 211-232

  10. Muscarinic Mechanisms in Psychotic Disorders

    • David L. McKinzie, Frank P. Bymaster
    Pages 233-265

  11. Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications

    • Joseph T. Coyle, Alo Basu, Michael Benneyworth, Darrick Balu, Glenn Konopaske
    Pages 267-295

  12. Metabotropic Glutamate Receptors for New Treatments in Schizophrenia

    • E. J. Herman, M. Bubser, P. J. Conn, C. K. Jones
    Pages 297-365

  13. Glycine Transport Inhibitors in the Treatment of Schizophrenia

    • Daniel C. Javitt
    Pages 367-399

  14. Nicotinic Receptors and Functional Regulation of GABA Cell Microcircuitry in Bipolar Disorder and Schizophrenia

    • Francine M. Benes
    Pages 401-417

  15. Development of Disease-Modifying Treatment of Schizophrenia

    • Anton Bespalov, Corinna Klein, Berthold Behl, Gerhard Gross, Hans Schoemaker
    Pages 419-442

  16. Back Matter

    Pages 443-455
    Download chapter PDF
Back to top

Keywords

About this book

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.

Reviews

From the reviews:

“The target audience … is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. … This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a ‘one disease’ perspective.” (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

Editors and Affiliations

  • Dept. Psychiatry, University of California San Diego, La Jolla, USA

    Mark A. Geyer

  • Institut für Pharmakologie, Universität, Neuroscience Research, Abbott GmbH & Co. KG, Ludwigshafen, Germany

    Gerhard Gross

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation